---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-3"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-3. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 92 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence/rapide-3"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-3

<a id="heading-3.1.1"></a>

## 3.1.1 RAPIDe-3

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Trial aim

> “The RAPIDe-3 phase 3 trial aimed to assess the efficacy and safety of oral deucrictibant immediate-release capsule for on-demand treatment of attacks in adolescents and adults with hereditary angioedema.”
> “Our phase 3 trial was carried out to confirm the efficacy and safety of deucrictibant in a larger patient population in all subtypes of hereditary angioedema, including those with normal C1 inhibitor.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.1-2"></a>

#### Registry brief summary

> “This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.1-3"></a>

#### Objective stated in the AAAAI 2026 results poster

> “To assess the efficacy, safety, and tolerability of oral deucrictibant immediate-release (IR) capsule for on-demand treatment of attacks in adolescents and adults with HAE, including participants with HAE with normal C1 inhibitor (HAE-nC1INH).”

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Sites, countries, and enrollment period in the publication

> “The trial was conducted at 59 sites across 24 countries on six continents”
> “Between April 4, 2024, and Sept 1, 2025, 149 people were assessed for eligibility”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.2-2"></a>

#### Countries in each geographical region

> “Geographical region of North America includes Canada, Puerto Rico, and the USA; Europe includes Austria, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, and the UK; rest of world includes Argentina, Australia, Brazil, Hong Kong, Japan, Saudi Arabia, South Africa, South Korea, and Türkiye.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.2-3"></a>

#### Patient association input on countries and sites

> “A global network of patient associations provided recommendations of countries, potential study sites, and study investigators.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.2-4"></a>

#### Registry dates, status, and number of locations

> “Study Start (Actual) 2024-02-26 Primary Completion (Actual) 2025-10-17 Study Completion (Actual) 2025-10-17”
> “This study has 76 locations”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.2-5"></a>

#### Trial initiation and topline timing reported by the company

> “Following the readout of RAPIDe-2, we initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.1.2-6"></a>

#### Target enrollment reached

> “reached target enrollment in March 2025”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-3.1.1.2-7"></a>

#### Topline announcement date

> “ZUG, Switzerland, December 3, 2025 – Pharvaris (Nasdaq: PHVS)”
> “today announced RAPIDe-3 pivotal data confirming the potential of deucrictibant’s differentiated profile for the on-demand treatment of HAE attacks.”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Crossover design, randomization, and stratification

> “The trial was conducted using a randomised, double-blind, two-period, two-sequence crossover design (2 × 2 crossover) comparing deucrictibant with placebo.”
> “All participants were randomly allocated 1:1 to one of two double-blind crossover sequences of deucrictibant–placebo or placebo–deucrictibant to treat two qualifying attacks (figure 1; appendix p 17), stratified by age (≥12 to <18 years or ≥18 years) and concomitant long-term prophylaxis use at the time of screening (yes or no).”
> “Randomisation of treatment sequence assignment was done via an interactive response technology system.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-2"></a>

#### Masking and study drug packaging

> “Participants, investigators, site personnel, and the sponsor were masked to treatment assignment.”
> “Each wallet contained one single capsule (either deucrictibant or placebo).”
> “Wallets and capsules of deucrictibant and placebo were identical to maintain masking.”
> “Treatment unmasking was permitted in the case of emergency as determined by the investigator.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-3"></a>

#### Washout between treated attacks

> “Following attack treatment with study drug (or after the second dose of study drug or conventional rescue medication, if used), a washout period of at least 72 h before treatment of the next attack with study drug was required to avoid potential carry-over effects.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-4"></a>

#### Non-attack pharmacokinetic dose in adolescents

> “Before random allocation, adolescent participants received a single oral deucrictibant capsule in a non-attack state for pharmacokinetic assessment.”
> “The pharmacokinetic profile of deucrictibant immediate-release capsule in adults was previously described.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-5"></a>

#### Electronic patient-reported outcomes and attack qualification by the investigator

> “All participants used a handheld device to record electronic patient-reported outcomes (ePRO) for attack symptom ratings and other attack-related information, including study drug intake and rescue medication use.”
> “Participants first entered their attack information into the ePRO device. Each attack was then assessed and qualified by the investigator during a telephone call or other live communication.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-6"></a>

#### Registry design details

| Field | Reported value |
| --- | --- |
| Other study ID number | “PHA022121-C306” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.3-7"></a>

#### Registry study phases

> “The study consists of a Screening Phase during which eligibility is confirmed, a Treatment Phase in which participants will be randomized and receive double blinded study drug to treat 2 qualifying HAE attacks (i.e., 2 Treatment Periods within the Treatment Phase), and an End-of-Study Follow-up Phase after the second attack treated with study drug.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.3-8"></a>

#### Optional rollover to the open-label extension

> “Data from end-of-study visit could be used to qualify the participant for an OLE study with deucrictibant.”
> “Rollover to the OLE was optional.”

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion criteria in the publication

> “Adolescents (aged ≥12 to <18 years) and adults (aged ≥18 to ≤75 years) with hereditary angioedema, including those with normal C1 inhibitor associated with a documented genetic variant, at least two attacks within the last 3 months before screening, and experience with effectively using conventional on-demand therapies for hereditary angioedema attacks were eligible.”
> “Participants using concomitant hereditary angioedema long-term prophylaxis were also eligible.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.4-2"></a>

#### Exclusion criteria in the publication

> “Participants were excluded in cases of any diagnosis of other forms of angioedema or previous on-demand hereditary angioedema treatment with deucrictibant.”
> “Pregnant and breastfeeding women were not eligible.”
> “Women of childbearing potential were eligible if sexually abstinent or using medically acceptable contraception.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.4-3"></a>

#### Registry inclusion criteria

> “Male or female, aged ≥12 to ≤75 years at the time of providing written informed consent/assent.”
> “Diagnosis of HAE-1/2/3.”
> “History of at least 2 HAE attacks in the last 3 months before screening.”
> “Experience with using standard-of-care treatment to effectively manage on-demand treatment for HAE attacks.”
> “Participants on long-term prophylactic therapy with plasma-derived C1-INH (danazol, anti-fibrinolytics, berotralstat, or lanadelumab) must be on a stable dose and regimen and intend to remain on the same dose for 6 months before screening and the duration of the study.”
> “For adolescent participants aged ≥12 and <18 years of age: body weight ≥40 kg.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.4-4"></a>

#### Registry exclusion criteria: organ function, CYP3A4 medicines, and prior therapies

> “Use of attenuated androgens for short-term prophylaxis within 2 weeks before screening.”
> “Abnormal hepatic function.”
> “Abnormal renal function (eGFR <60 ml/min/1.73 m2).”
> “Has received prior on-demand HAE treatment with deucrictibant.”
> “Prior gene therapy for any indication at any time.”
> “Use of concomitant medications with systemic absorption that are strong inhibitors of CYP3A4 or strong inducers of CYP3A4 within the last 30 days, or within 5 half-lives (whichever is longer) of the time of randomization.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.4-5"></a>

#### Qualifying attacks and exclusion of severe laryngeal attacks

> “Qualifying attacks were defined as either non-laryngeal attacks, with at least one symptom item score of 20 or more on the angioedema symptom rating scale (AMRA) assessment, which measures skin swelling, skin pain, and abdominal pain, as described below, or non-severe laryngeal attacks without breathing difficulties or stridor.”
> “Attacks of any severity (mild, moderate, and severe) were included, barring severe laryngeal attacks, consistent with other recent phase 3 trials of on-demand treatment in hereditary angioedema,”
> “due to the risks of random assignment to treatment with double-masked placebo.”
> “Adolescent participants with laryngeal attacks, regardless of severity, and adult participants with severe laryngeal attacks (those with symptoms of breathing difficulties or stridor) were instructed to immediately take their conventional on-demand therapy instead of the study drug and to seek medical care urgently.”
> “Attacks that did not meet the qualification criteria were treated with conventional on-demand therapy.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Study drug and dose

> “The RAPIDe-3 phase 3, randomised, double-blind, placebo-controlled crossover trial evaluated the efficacy and safety of oral deucrictibant immediate-release capsule 20 mg (henceforth referred to as deucrictibant).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.5-2"></a>

#### Registry treatment sequences and intervention

> “Deucrictibant administered for first HAE attack, placebo administered for second HAE attack.”
> “Placebo administered for first HAE attack, deucrictibant administered for second HAE attack.”
> “Deucrictibant Soft Capsules for Oral Use”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.5-3"></a>

#### Self-administration after investigator qualification

> “Following investigator-confirmed qualification and before administration of the study drug, participants completed their pre-treatment assessments, including PGI-S and AMRA ratings, using the ePRO instruments on the electronic device.”
> “During the qualification call with the investigator or immediately following, patients then self-administered the study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.5-4"></a>

#### Second capsule and rescue medication rules

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks.”
> “For laryngeal attacks, a second capsule of study drug was not permitted, and rescue medication was allowed at any time.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.5-5"></a>

#### Registry definition of rescue medication

> “Rescue medication is defined as the participant's usual acute on-demand HAE treatment taken if symptoms persist or progress after study drug administration.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Time to Onset of Symptom Relief by Patient Global Impression of Change as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint: definition in the publication

> “The primary endpoint was time to onset of symptom relief, defined as achieving a rating of at least a little better on the PGI-C scale for two consecutive timepoints within 12 h post-treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoint: registry definition and time frame

> “Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment.”
> “The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.”
> “Pre-treatment to 12 hours post-treatment.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.6.1-3"></a>

##### PGI-C and PGI-S scales

> “The Patient Global Impression of Change (PGI-C) was used to evaluate the change in the hereditary angioedema attack symptoms at the time of the assessment compared with pre-treatment (last symptom assessment before study drug administration) and was scored on a seven-point Likert scale with possible responses of much better, better, a little better, same, a little worse, worse, and much worse.”
> “The Patient Global Impression of Severity (PGI-S) was used to evaluate the severity of hereditary angioedema attack symptoms at the time of the assessment and was scored on a five-point Likert scale with possible responses of none, mild, moderate, severe, and very severe.”
> “The PGI-C and PGI-S are validated instruments for evaluating patient-reported outcomes that have been previously used in clinical trials in hereditary angioedema to evaluate a patient's global perception of changes in and severity of their attack manifestations, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-4"></a>

##### Assessment schedule after study drug

> “Following study drug administration, patients completed the PGI-C, the PGI-S, and AMRA assessments using the ePRO device at 15 min and 30 min post-treatment, then every 30 min through to 4 h, every 60 mins through to 12 h, every 120 mins through to 24 h, and at 36 h and 48 h post-treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-5"></a>

##### Selection of PGI-C for the primary endpoint: mixed methods patient-reported outcome study

> “When comparing different definitions of time to onset of symptom relief, PGI-C had greater sensitivity in detecting early symptom relief yet remained comparable to AMRA symptom relief endpoints.”
> “For the PGI-C, participants (n = 19) discussed perceived meaningful improvement from their worst score and associated this with a reduction or improvement in symptoms and knowledge the attack would not worsen.”
> “On the basis of the association between AMRA and PGI-C established in this study, the phase 3 RAPIDe-3 trial used the PGI-C to define the primary efficacy endpoint.”

Source: [Mendivil et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12953491/)

<a id="topic-3.1.1.6.1-6"></a>

##### PGI-C rating of a little better as a clinically meaningful milestone: patient interviews and phase 2 sebetralstat data

> “Patient interviews revealed a strong preference (71%) for the Patient Global Impression of Change (PGI‐C) over other measures and indicated a rating of "A Little Better" as a clinically meaningful milestone.”
> “Feedback from a patient advisory board initially identified the PGI‐C as a preferred PRO for assessing symptom relief in HAE, and follow‐up structured interviews highlighted that the rating of "A Little Better" on the PGI‐C best represented the earliest signs of symptom relief for most patients.”

Source: [Cohn et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10476273/)

<a id="topic-3.1.1.6.1-7"></a>

##### Core outcome set for trials of acute treatment

> “In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of five key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction.”

Source: [Petersen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38609017/)

<a id="topic-3.1.1.6.1-8"></a>

##### Conformance of RAPIDe-3 endpoints with the AURORA core outcome set

> “To investigate deucrictibant further, we conducted a phase 3 trial with prespecified endpoints conforming to the set of core outcomes recommended for inclusion in on-demand treatment trials by the recent AURORA Delphi Consensus, which were developed with input from patients with hereditary angioedema, and included measurement of changes in symptom severity, end of progression, and duration of treatment response based on need for additional treatment.”
> “Additionally, to the best of our knowledge, this is the first and only trial with prespecified endpoints designed to conform to all core outcomes recommended for inclusion in on-demand hereditary angioedema trials by the recent international AURORA Delphi Consensus.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-9"></a>

##### Key secondary endpoints: definitions in the publication

> “Secondary efficacy endpoints were measured using the PGI-C, PGI-S, and AMRA instruments, and included: proportion of study drug-treated attacks reaching onset of symptom relief at 4 h (PGI-C), time to substantial symptom relief, defined as the time to a PGI-C rating of at least better for two consecutive timepoints within 12 h post-treatment, reduction in attack severity within 12 h (PGI-S), complete symptom resolution within 48 h (PGI-S), end of progression of symptoms within 12 h (PGI-C and AMRA), substantial symptom relief defined as time to 50% or greater reduction in AMRA composite score from pre-treatment for two consecutive timepoints within 12 h post-treatment, and almost complete or complete symptom resolution within 24 h (AMRA).”
> “Remaining secondary endpoints were the proportion of attacks achieving almost complete or complete symptom resolution within 24 h (AMRA), the proportion of attacks reaching complete symptom resolution with one capsule (PGI-S), and the proportion of attacks using rescue medication.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-10"></a>

##### Key secondary endpoints: first six in the testing hierarchy

> “The primary and first 6 of 11 hierarchical order-ranked secondary endpoints.”

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

| Secondary endpoint | Definition |
| --- | --- |
| “Proportion of attacks achieving onset of symptom relief” | “Proportion of study-drug treated attacks achieving a PGI-C rating of at least "a little better" at 4 hours post-treatment” |
| “Time to substantial symptom relief” | “Time to a PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment” |
| “Time to reduction in attack severity” | “Time to a ≥1-level reduction in PGI-S score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment” |
| “Time to complete symptom resolution” | “Time to PGI-S rating of "none" within 48 hours post-treatment” |
| “Time to end of progression” | “Time to the earliest post-treatment timepoint after which all subsequent PGI-C ratings are stable or improved within 12 hours” |
| “Use of conventional on-demand treatment as rescue medication” | “Proportion of study-drug treated attacks using conventional on-demand treatment as rescue medication to treat an attack within 24 hours post-treatment” |

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="topic-3.1.1.6.1-11"></a>

##### Key secondary endpoints: registry definitions

| Outcome measure | Measure description |
| --- | --- |
| “Proportion of study drug-treated attacks achieving PGI-C rating of at least "a little better" at 4 hours post-treatment.” | “The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.” |
| “Time to substantial symptom relief, defined as achieving PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment.” | “The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.” |
| “Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S).” | “Defined as achieving ≥1 point reduction in PGI-S (5-point scale) from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.” |
| “Time to complete symptom resolution, defined as achieving PGI-S rating of "none" within 48 hours post-treatment.” | “The PGI-S (5-point scale) is used to evaluate the severity of HAE attack symptoms.” |
| “Time to End of Progression (EoP) in attack symptoms within 12 hours.” | “EoP time defined as the earliest post-treatment timepoint after which all subsequent PGI-C ratings are stable or improved.” |
| “Proportion of study drug-treated attacks requiring rescue medication within 24 hours post-treatment.” | “Rescue medication is defined as the participant's usual acute on-demand HAE treatment taken if symptoms persist or progress after study drug administration.” |
| “Proportion of attacks achieving symptom resolution.” | “Defined as achieving PGI-S rating of "none" with one dose of study drug at 24 hours post-treatment.” |
| “Time to substantial symptom relief by Angioedema Symptom Rating Scale (AMRA).” | “Defined as a ≥50% reduction in AMRA composite score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.” |
| “Time to almost complete or complete symptom relief by AMRA.” | “Defined as all item scores in AMRA having a value ≤10 for 2 consecutive timepoints within 24 hours post-treatment.” |
| “Proportion of study drug-treated attacks reaching almost complete or complete symptom relief by AMRA.” | “Defined as all item scores in AMRA having a value ≤10 at 24 hours post-treatment.” |
| “Time to EoP in attack symptoms within 12 hours.” | “Defined as the earliest post-treatment timepoint after which every individual AMRA item is stable or improved at all subsequent timepoints.” |

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.6.1-12"></a>

##### Key secondary endpoint: end of progression, definition and rationale

> “End of progression (EoP): defined as the earliest post-treatment timepoint after which attack manifestations stop worsening further, which marks the earliest evidence of treatment effects.”
> “It can serve as a clinically meaningful indicator of attacks starting to evolve toward relief and resolution.”
> “Achieving EoP can also offer psychological reassurance by reducing the uncertainty associated with HAE attack escalation.”

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

> “To our knowledge, the inclusion of end of progression of symptoms measured in RAPIDe-3 as a prespecified endpoint, marking the earliest evidence of treatment effects, is the first instance in a hereditary angioedema on-demand trial.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-13"></a>

##### Key secondary endpoint: end of progression, psychometric validation with RAPIDe-3 data

> “Psychometric analyses of patient-reported outcomes from the Phase 3 RAPIDe-3 trial collectively support the validity of a Patient Global Impression of Change (PGI-C)–based definition of end of progression (EoP) of hereditary angioedema (HAE) attack symptoms based on the Patient Global Impression of Severity (PGI-S) and three-item Angioedema syMptom Rating scAle (AMRA-3) as anchor measures.”
> “Analyses were performed for a total of 194 attacks (192 non-laryngeal and 2 laryngeal).”
> “PGI-C was strongly associated with latent changes in HAE severity (β = 0.824), explaining 68% of variance in PGI-C; these findings support the use of PGI-C as a valid instrument for evaluating EoP.”
> “Within-person correlations between PGI-C and change in PGI-S (correlation for repeated measures, rrm = 0.765) and between PGI-C and percent change in AMRA-3 (rrm = 0.839) exceeded the 0.30 threshold required for use as anchors (Table 4).”

Source: [Cohn et al. (2026)](https://ir.pharvaris.com/static-files/8ea05186-a535-4842-bb06-c31a4994fbea)

<a id="topic-3.1.1.6.1-14"></a>

##### Key secondary endpoints measured with the angioedema symptom rating scale

> “The AMRA was adapted from the visual analogue scale (VAS), which had been previously used in earlier clinical trials of on-demand treatments for hereditary angioedema, to measure symptom severity at the time of the assessment on a scale from 0 (no symptoms) to 100 (worst possible symptoms).”
> “VAS-3 symptom and VAS 5-symptom assessments have since been adapted into electronic versions and renamed AMRA-3 and AMRA-5, respectively.”
> “AMRA-3, which rates the severity of three key attack symptoms (skin pain, skin swelling, and abdominal pain) was used to evaluate non-laryngeal attacks. AMRA-5, which additionally includes the symptoms of voice change and difficulty swallowing, was used to evaluate laryngeal attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-15"></a>

##### Safety endpoints and the 3-day reporting window

> “Safety endpoints were incidence of treatment-emergent adverse events and of treatment-emergent serious adverse events, and change from baseline in clinical laboratory findings, vital signs, and electrocardiogram parameters.”
> “Due to the duration of exposure to deucrictibant following administration of the immediate-release capsule (8 h or longer), treatment-emergent adverse events reported within 3 days of study drug administration were considered temporally clinically relevant.”
> “A treatment-emergent adverse event was defined as an adverse event from the first study drug administration through to the end of study visit.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Sample size calculation and planned enrollment

> “Assuming median time to onset of symptom relief of 2 h for deucrictibant and 5 h for placebo, and a within-participant correlation of 0·2, statistical simulations indicated that a total of 60 participants in the primary efficacy analysis set would provide at least 90% power to detect a treatment difference in time to onset of symptom relief by PGI-C at a two-sided significance level of 0·05.”
> “Accounting for participants who would not treat an attack in each of the two attack periods, the study planned to enrol approximately 120 participants to achieve the target of at least 60 participants in the primary efficacy analysis set (two treated attacks, one per crossover period).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment stated by the company, May 2025

> “RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), reached target enrollment in March 2025; the study continues to assess HAE attacks in approximately 120 participants.”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-3.1.1.7.1-3"></a>

##### Registry actual enrollment

> “Enrollment (Actual) 134”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants and attacks analyzed in each analysis set

> “The primary efficacy analysis set included 88 participants who had one deucrictibant-treated and one placebo-treated attack, for a total of 176 attacks (appendix p 23).”
> “Prespecified sensitivity analyses, including treatment effect estimates, were done for all 113 participants with at least one study drug-treated attack, for a total of 201 attacks.”
> “N refers to the total number of participants with at least one dose of study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.1-5"></a>

##### Safety analysis set by treatment received

> “Data based on Safety Analysis Set, which includes all enrolled participants who received any dose of study drug.”
> “One participant randomized to the deucrictibant-placebo sequence was incorrectly administered placebo for the first attack; study closure occurred before the participant experienced a second attack.”

Source: [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404)

<a id="topic-3.1.1.7.1-6"></a>

##### Observed placebo response compared with the sample size assumption

> “The median time to onset of symptom relief in the placebo group was longer than assumed in the sample size calculation as the planning assumption was intentionally conservative and derived from the phase 2 RAPIDe-1 trial using endpoint mapping results from the endpoint validation study.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Primary efficacy, expanded, and safety analysis sets

> “Following the statistical analysis plan, primary efficacy analyses for both time-to-event and binary endpoints were conducted using the primary efficacy analysis set, comprising all randomised participants who treated both attacks with study drug in accordance with the 2 × 2 crossover design.”
> “Sensitivity and subgroup analyses employed an expanded analysis set including all participants who treated at least one attack with study drug, as these analyses did not require within-participant paired comparisons and the broader inclusion mitigated potential sample size limitations in subgroup evaluations.”
> “Safety analyses included all participants who received at least one dose of study drug; comparisons are descriptive.”
> “Summaries and analyses using the primary efficacy analysis set and the set of all participants with at least one treated attack were based on planned treatment. Summaries and analyses using the safety analysis set were based on actual treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-2"></a>

##### Statistical tests for time-to-event and binary endpoints

> “Time-to-event endpoints were primarily evaluated using the prespecified Gehan's generalised Wilcoxon test, which provided a robust, non-parametric, paired comparison.”
> “Time-to-event endpoint medians were estimated for deucrictibant and placebo, respectively, using the Kaplan–Meier method.”
> “Prespecified sensitivity analyses included linear mixed-effects models applied to Gehan score-transformed event times and marginal Cox proportional hazards model with robust variance estimation.”
> “Binary endpoints were primarily evaluated using the Prescott test, a non-parametric paired comparison method used for 2 × 2 crossover designs.”
> “Prespecified sensitivity analyses were performed using generalised estimating equation models with a logit link.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-3"></a>

##### Multiplicity control by fixed-sequence gatekeeping

> “Formal hierarchical statistical testing was performed on the primary and secondary efficacy endpoints.”
> “A gatekeeping procedure was used to control study-wise type 1 error rate at a two-sided alpha of 0·05 across all endpoints tested, following the order of first testing the primary endpoint, then the secondary endpoints in the fixed order as predefined in the trial protocol and statistical analysis plan (appendix).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-4"></a>

##### Intercurrent events and missing data: composite variable strategy

> “An intercurrent event was defined as the use of rescue medication or selected prohibited medication after an attack was treated with study drug.”
> “Intercurrent events were handled using a composite variable strategy for the primary and secondary endpoints that considered intercurrent events a treatment failure.”
> “For such attacks, time-to-event endpoints were right censored at the end of the data collection window for the relevant timeframe, and binary endpoints were classified as unfavourable outcomes, regardless of whether rescue or prohibited medication use occurred before or after the endpoint was reached.”
> “Missing data at the end of follow-up were addressed through right censoring instead of imputation, consistent with the prespecified estimand and survival analysis principles.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-5"></a>

##### Supplementary analyses: per-protocol set and treatment policy strategy

> “Prespecified supplementary analyses on the primary endpoint included an analysis using the per-protocol analysis set and an analysis using a treatment policy strategy approach on the primary efficacy analysis set and on the set of all participants with at least one treated attack.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Screening, randomization, and treated attacks

> “Between April 4, 2024, and Sept 1, 2025, 149 people were assessed for eligibility, and 134 eligible participants (ten [7%] adolescents and 124 [93%] adults) were enrolled and randomly allocated at 59 sites across 24 countries on six continents (figure 1; appendix p 22).”
> “113 participants treated 201 attacks. The primary efficacy analysis included 88 participants with paired treated attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.1-2"></a>

##### Randomized sequences and attacks treated in each sequence

> “N=134 enrolled (124 adults, 10 adolescents)”
> “N=68 randomized to placebo”
> “N=53 treated one attack with placebo”
> “N=41 treated one attack with deucrictibant”
> “N=66 randomized to deucrictibant”
> “N=60 treated one attack with deucrictibant”
> “N=47 treated one attack with placebo”
> “N=88 paired attacks (Primary Efficacy Analysis Set)”

Source: [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404)

<a id="topic-3.1.1.8.1-3"></a>

##### Trial closure before all participants treated two attacks

> “The sponsor ended the trial after the prespecified number of participants with paired treated attacks was met and allowed participants to transition to the open-label extension (NCT05396105) before all participants completed treatment of two attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.1-4"></a>

##### Protocol deviations

> “There were no protocol amendments or deviations from the protocol that affected statistical analysis conclusions (appendix p 24), as evidenced by consistency of the outcomes from the sensitivity and supplemental analyses with the prespecified per-protocol analyses.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### All randomized participants: sex, age, and HAE with normal C1 inhibitor

> “For the 134 eligible participants, 58 (43%) were male and 76 (57%) were female, and the median age was 38·0 years (IQR 27·0–50·0).”
> “Of the four (3%) participants with hereditary angioedema with normal C1 inhibitor, two carried a variant in the plasminogen gene and two carried a variant in the coagulation factor XII gene.”
> “Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis at enrolment and during the study.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.2-2"></a>

##### All randomized participants: demographic and disease characteristics, 134 participants

| Characteristic | All randomized participants (N=134) |
| --- | --- |
| Age in years, mean (SD) | “39.0 (14.7)” |
| Age ≥12 to <18 years, n (%) | “10 (7.5)” |
| Age ≥18 to <65 years, n (%) | “116 (86.6)” |
| Age ≥65 years, n (%) | “8 (6.0)” |
| Female, n (%) | “76 (56.7)” |
| BMI, mean (SD) | “26.5 (5.9)” |
| White, n (%) | “93 (69.4)” |
| Asian, n (%) | “19 (14.2)” |
| Black or African American, n (%) | “10 (7.5)” |
| Europe, n (%) | “56 (41.8)” |
| Rest of world, n (%) | “40 (29.9)” |
| North America, n (%) | “38 (28.4)” |
| Years since HAE diagnosis, mean (SD) | “17.7 (13.0)” |
| Attacks within 3 months before screening, mean (SD) | “4.4 (3.3)” |
| HAE-C1INH type 1, n (%) | “118 (88.1)” |
| HAE-C1INH type 2, n (%) | “10 (7.5)” |
| Unspecified HAE-C1INH type 1 or 2, n (%) | “2 (1.5)” |
| HAE-nC1INH, n (%) | “4 (3.0)” |
| Current long-term prophylaxis use, n (%) | “31 (23.1)” |

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

> “LTP medication includes lanadelumab (13 [9.7%]), berotralstat (8 [6.0%]), complement c1 esterase inhibitor (6 [4.5%]), and other (4 [3.0%]).”

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="topic-3.1.1.8.2-3"></a>

##### Participants with at least one treated attack: demographic and disease characteristics by treatment, 113 participants

> “Demographics and baseline characteristics of participants with at least one treated attack”
> “Participants may be represented in multiple columns.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Characteristic | Deucrictibant (n=101) | Placebo (n=100) | Overall (n=113) |
| --- | --- | --- | --- |
| Age, years, median (IQR) | “36·0 (27·0–49·0)” | “36·5 (28·0–50·0)” | “36·0 (27·0–50·0)” |
| Male | “46 (46%)” | “46 (46%)” | “51 (45%)” |
| Female | “55 (54%)” | “54 (54%)” | “62 (55%)” |
| White | “70 (69%)” | “70 (70%)” | “80 (71%)” |
| Asian | “17 (17%)” | “16 (16%)” | “17 (15%)” |
| Black or African American | “4 (4%)” | “6 (6%)” | “6 (5%)” |
| North America | “21 (21%)” | “26 (26%)” | “28 (25%)” |
| Europe | “47 (47%)” | “41 (41%)” | “50 (44%)” |
| Rest of world | “33 (33%)” | “33 (33%)” | “35 (31%)” |
| BMI, kg/m2, median (IQR) | “25·2 (22·3–28·2)” | “25·6 (22·5–29·2)” | “25·5 (22·4–28·9)” |
| HAE-C1INH-type 1 | “90 (89%)” | “91 (91%)” | “102 (90%)” |
| HAE-C1INH-type 2 | “8 (8%)” | “8 (8%)” | “8 (7%)” |
| HAE-nC1INH | “2 (2%)” | “0” | “2 (2%)” |
| Unspecified HAE-C1INH type 1 or 2 | “1 (1%)” | “1 (1%)” | “1 (1%)” |
| Time since diagnosis, years, median (IQR) | “15·0 (7·0–24·0)” | “15·5 (7·0–24·5)” | “15·0 (7·0–24·0)” |
| Concomitant long-term prophylaxis: yes | “20 (20%)” | “24 (24%)” | “26 (23%)” |
| Long-term prophylaxis: lanadelumab | “8 (8%)” | “10 (10%)” | “11 (10%)” |
| Long-term prophylaxis: berotralstat | “5 (5%)” | “7 (7%)” | “7 (6%)” |
| Long-term prophylaxis: C1-esterase inhibitor | “4 (4%)” | “5 (5%)” | “5 (4%)” |
| Long-term prophylaxis: danazol | “3 (3%)” | “2 (2%)” | “3 (3%)” |
| Attacks in the 3 months before screening: 2–5 | “72 (71%)” | “71 (71%)” | “83 (73%)” |
| Attacks in the 3 months before screening: 6–10 | “19 (19%)” | “19 (19%)” | “20 (18%)” |
| Attacks in the 3 months before screening: 11–15 | “6 (6%)” | “6 (6%)” | “6 (5%)” |
| Attacks in the 3 months before screening: 16–20 | “2 (2%)” | “2 (2%)” | “2 (2%)” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.2-4"></a>

##### Primary efficacy analysis set: demographic and disease characteristics, 88 participants

> “Of these, 47 (53%) participants were female and 41 (47%) were male, and 60 (68%), 16 (18%), 4 (5%), and 1 (1%) were White, Asian, Black, and American Indian or Alaska Native, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Characteristic | Primary efficacy analysis group (N=88) |
| --- | --- |
| Age in years, mean (SD) | “38.7 (13.6)” |
| Age ≥12 to <18 years, n (%) | “5 (5.7)” |
| Age ≥18 to <65 years, n (%) | “80 (90.9)” |
| Age ≥65 years, n (%) | “3 (3.4)” |
| Female, n (%) | “47 (53.4)” |
| North America, n (%) | “19 (21.6)” |
| Europe, n (%) | “38 (43.2)” |
| Rest of world, n (%) | “31 (35.2)” |
| Years since HAE diagnosis, mean (SD) | “17.3 (12.24)” |
| HAE-C1INH type 1, n (%) | “79 (89.8)” |
| HAE-C1INH type 2, n (%) | “8 (9.1)” |
| Unspecified HAE-C1INH type 1 or 2, n (%) | “1 (1.1)” |
| Current long-term prophylaxis use, n (%) | “18 (20.5)” |

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

<a id="topic-3.1.1.8.2-5"></a>

##### Attack type, location, and severity at pre-treatment, 201 treated attacks

> “Of all 201 attacks treated with study drug, 181 (90%) were treated by participants with hereditary angioedema type 1, 16 (8%) by participants with hereditary angioedema type 2, and two (1%) by participants with normal C1 inhibitor (both carrying a variant in the plasminogen gene), respectively (table 1).”
> “For the 101 attacks treated with deucrictibant and 100 treated with placebo, respectively, the attack primary location was reported as peripheral (58 [57%] of 101 vs 54 [54%] of 100), abdominal (38 [38%] of 101 vs 42 [42%] of 100), and non-severe laryngeal (two [2%] of 101 vs none), and severity as mild (18 [18%] of 101 vs 12 [12%] of 100), moderate (60 [59%] of 101 vs 47 [47%] of 100), and severe or very severe (17 [17%] of 101 vs 29 [29%] of 100) at pre-treatment (appendix p 25).”
> “These distributions of attacks were consistent with the primary efficacy analysis set for both groups (appendix p 25).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary endpoint: time to onset of symptom relief, primary efficacy analysis set of 88 participants with paired attacks

> “Onset of symptom relief, the primary endpoint, was met significantly faster with deucrictibant compared with placebo (figure 2A; table 2), with a median time of 1·28 h (95% CI 1·05 to 1·52; p<0·0001) versus over 12 h (5·82 to >12), respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-2"></a>

##### Primary and secondary endpoints by PGI-C and PGI-S, primary efficacy analysis set of 88 participants with paired attacks

> “Primary and secondary efficacy endpoints in the primary efficacy analysis set”
> “n refers to the number of randomly allocated participants who had two attacks treated with study drug following the 2 × 2 crossover design. N' refers to the number of participants with post-treatment data within the specified timeframe.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Endpoint and statistic | Deucrictibant N' | Deucrictibant result | Placebo N' | Placebo result | p value |
| --- | --- | --- | --- | --- | --- |
| Primary: time to onset of symptom relief (PGI-C), median time (95% CI), h | “83/88” | “1·28 (1·05 to 1·52)” | “87/88” | “>12 (5·82 to >12)” | “<0·0001” |
| Attacks meeting onset of symptom relief at 4 hours (PGI-C), n (%) | “83/88” | “69/83 (83%)” | “87/88” | “24/87 (28%)” | “<0·0001” |
| Time to substantial symptom relief (PGI-C), median time (95% CI), h | “83/88” | “2·85 (2·08 to 3·35)” | “87/88” | “>12 (10·30 to >12)” | “<0·0001” |
| Time to reduction in attack severity (PGI-S), median time (95% CI), h | “83/88” | “2·41 (1·70 to 2·98)” | “84/88” | “>12 (12·34 to >12)” | “<0·0001” |
| Time to complete symptom resolution (PGI-S), median time (95% CI), h | “83/88” | “11·95 (8·61 to 21·79)” | “87/88” | “>48 (>48 to >48)” | “<0·0001” |
| Time to end of progression (PGI-C), median time (95% CI), min | “83/88” | “17·47 (16·27 to 19·17)” | “87/88” | “228·67 (61·82 to 599·60)” | “<0·0001” |
| Complete symptom resolution with one dose at 24 hours (PGI-S), n (%) | “83/88” | “50/83 (60%)” | “87/88” | “13/88 (15%)” | “<0·0001” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-3"></a>

##### Secondary endpoints by PGI-C and PGI-S: median times, primary efficacy analysis set

> “Endpoints of time to substantial symptom relief, reduction in attack severity, complete symptom resolution, and end of progression, as assessed by PGI-C or PGI-S, were also reached faster for deucrictibant-treated attacks than for placebo-treated attacks (p<0·0001 for all endpoints).”
> “Median times to each secondary endpoint for deucrictibant and placebo, respectively, were 2·85 h (95% CI 2·08 to 3·35) and more than 12 h (10·30 to >12) to substantial symptom relief, 2·41 h (1·70 to 2·98) and more than 12 h (12·34 to >12) to reduction in attack severity, 11·95 h (8·61 to 21·79) and more than 48 h (>48 to >48) to complete symptom resolution, and 17·47 min (16·27 to 19·17) and 228·67 min (61·82 to 599·60) to end of progression (figure 2B–E; table 2).”
> “The percentage of attacks meeting onset of symptom relief at 4 h post-treatment was 69 (83%) of 83 for deucrictibant and 24 (28%) of 87 for placebo (p<0·0001; table 2).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-4"></a>

##### Company summary of the primary and secondary results, efficacy analysis of 88 participants with paired attacks

> “The efficacy analysis included paired attacks (one participant contributed one deucrictibant-treated attack and one placebo-treated attack) from 88 participants.”
> “time to complete attack resolution as measured by a PGI-S rating of "none" (11.95 hours vs. over 48 hours)”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.1.8.3-5"></a>

##### Time to complete symptom resolution, placebo median: topline statement, December 2025, superseded in March 2026

> “Median time to complete symptom resolution by PGI-S "none": 11.95 hours versus >24 hours (p<0.0001)”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="topic-3.1.1.8.3-6"></a>

##### End of progression median stated at NDA acceptance, July 2026

> “the median time to onset of symptom relief was 1.28 hours, to End of Progression™ (EoP) was 17.48 minutes”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-3.1.1.8.3-7"></a>

##### Secondary endpoints by AMRA, primary efficacy analysis set

> “Endpoints assessed using AMRA also showed faster times to substantial symptom relief, almost complete or complete symptom resolution, and end of progression with deucrictibant compared with placebo (all p<0·0001).”
> “Median times for deucrictibant and placebo-treated attacks, respectively, were 3·37 h (95% CI 2·56 to 4·95) and more than 12 h (>12 to >12) to substantial symptom relief, 6·94 h (4·70 to 13·44) and more than 24 h (>24 to >24) to almost complete or complete symptom resolution, and 25·25 min (17·82 to 30·25) and 272·09 min (147·57 to >720) to end of progression (appendix pp 19, 27).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-8"></a>

##### Attacks reaching each endpoint within its prespecified timeframe, primary efficacy analysis set

> “The primary endpoint and these secondary efficacy endpoints were met within the relevant prespecified timeframe by 82–93% for deucrictibant-treated attacks and 37–61% for placebo-treated attacks (appendix p 18).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-9"></a>

##### Single capsule and second capsule use, primary efficacy analysis set of 88 paired attacks

> “For the primary analysis of 88 paired attacks, 73 (83%) and 69 (78%) of 88 deucrictibant-treated attacks and 29 (33%) and 27 (31%) of 88 placebo-treated attacks were treated with a single capsule within 12 h and 24 h, respectively (appendix p 26).”
> “A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively (appendix p 26).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-10"></a>

##### Rescue medication use, primary efficacy analysis set

> “Conventional on-demand therapy as rescue medication was used within 12 h for six (7%) of 88 deucrictibant-treated attacks and 32 (36%) of 88 placebo-treated attacks (figure 3), and within 24 h for eight (9%) of 88 deucrictibant-treated attacks and 39 (44%) of 88 placebo-treated attacks (p<0·0001; figure 3; table 2).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Endpoint | Deucrictibant (n=88) | Placebo (n=88) | p value |
| --- | --- | --- | --- |
| Attacks using conventional on-demand therapy as rescue medication within 24 h, n (%) | “8/88 (9%)” | “39/88 (44%)” | “<0·0001” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-11"></a>

##### Complete symptom resolution with a single capsule at 24 hours, primary efficacy analysis set

> “At 24 h, the percentage of deucrictibant-treated attacks reaching complete symptom resolution with a single capsule was approximately four times higher compared with placebo-treated attacks (p<0·0001; table 2).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-12"></a>

##### Sustained response and single-capsule use among responding attacks, primary efficacy analysis set of 88 participants

> “The primary efficacy analysis set included 88 participants who had one deucrictibant-treated attack and one placebo-treated attack, for a total of 176 attacks.”
> “Study outcomes: time to onset of sustained symptom relief, time to sustained substantial symptom relief, sustained reduction in attack severity, and sustained complete symptom resolution, where a sustained response was defined as achieving and maintaining the efficacy endpoint across all remaining timepoints within the assessment duration.”
> “More than 95% of deucrictibant-treated attacks maintained achievement of the predefined clinical endpoints throughout the respective assessment periods”
> “Seventy-five of the 77 (97.4%) deucrictibant-treated attacks that achieved EoP within 12 hours were treated with a single capsule.”

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

<a id="topic-3.1.1.8.3-13"></a>

##### Sensitivity and supplementary analyses, 113 participants with at least one treated attack

> “Prespecified sensitivity analyses of the primary and secondary endpoints in the 113 participants with at least one study drug-treated attack yielded results that were consistent with the primary analyses (appendix pp 27–31), as did supplementary analyses of the primary endpoint using the per-protocol analysis set and using the treatment policy strategy analysis approach (appendix p 32).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-14"></a>

##### Subgroups by age, HAE type, long-term prophylaxis, and attack location and severity, participants with at least one treated attack

> “Sensitivity and subgroup analyses employed an expanded analysis set including all participants who treated at least one attack with study drug”
> “Outcomes were consistent across subgroups defined by age, hereditary angioedema types, whether concomitant long-term prophylaxis was used or not, and attack location and severity (appendix p 20).”
> “Efficacy outcomes were consistent across all clinically relevant subgroups defined according to age, geographical locations, hereditary angioedema type, concomitant use of long-term prophylaxis, and attack severities and locations.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-15"></a>

##### HAE with normal C1 inhibitor: two participants with one deucrictibant-treated attack each

> “In the two participants with hereditary angioedema with normal C1 inhibitor who each had one deucrictibant-treated attack, the time to onset of symptom relief was 1·53 h and 0·84 h, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-16"></a>

##### Regional subgroups, North America and Europe or rest of world: all participants with treated attacks

> “Analysis sets: subgroup analysis included all participants with treated attacks.”
> “In total, RAPIDe-3 enrolled 134 participants. The North American and European/Rest of World subgroups included 38 and 96 participants, respectively.”
> “In this regional subgroup analysis of the pivotal RAPIDe-3 trial, deucrictibant immediate-release (IR) capsule, an orally administered bradykinin B2 receptor antagonist, provided faster onset of symptom relief, reduction in attack severity, and complete resolution in both the North America and Europe/Rest of World subgroups compared with placebo.”

Source: [Adatia et al. (2026)](https://ir.pharvaris.com/static-files/9ecee56b-8c9c-475e-8f67-04661081af79)

| Region and endpoint | Deucrictibant | Placebo |
| --- | --- | --- |
| North America: time to onset of symptom relief, median | “1.20 hours (95% CI: 0.84, 1.84)” | “6.55 hours (95% CI: 1.88, >12)” |
| Europe/Rest of World: time to onset of symptom relief, median | “1.28 hours (95% CI: 1.04, 1.41)” | “>12 hours (95% CI: 5.74, >12)” |
| North America: time to reduction in attack severity, median | “2.43 hours (95% CI: 1.03, 5.12)” | “>12 hours (95% CI: 2.65, >12)” |
| Europe/Rest of World: time to reduction in attack severity, median | “2.53 hours (95% CI: 1.70, 2.98)” | “>12 hours (95% CI: 12.10, >12)” |
| North America: time to complete symptom resolution, median | “11.61 hours (95% CI: 2.94, 26.14)” | “>48 hours (95% CI: 17.21, >48)” |
| Europe/Rest of World: time to complete symptom resolution, median | “12.04 hours (95% CI: 8.64, 21.79)” | “>48 hours (95% CI: >48, >48)” |
| North America: onset of symptom relief at 4 hours | “77.8% (n=14/18)” | “46.2% (n=12/26)” |
| Europe/Rest of World: onset of symptom relief at 4 hours | “84.6% (n=66/78)” | “26.4% (n=19/72)” |

Source: [Adatia et al. (2026)](https://ir.pharvaris.com/static-files/9ecee56b-8c9c-475e-8f67-04661081af79)

<a id="topic-3.1.1.8.3-17"></a>

##### Pharmacokinetics in adolescents: ten participants in a non-attack state

> “Pharmacokinetic analyses were performed on samples from ten adolescent participants in non-attack state.”
> “Following a single capsule of deucrictibant, mean plasma levels reached the concentration estimated to provide 85% maximal response (EC85) of 13·8 ng/mL within 15 min and were maintained through to at least the last measured time point of 8 h.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

##### Health-related quality of life as exploratory endpoints

> “The primary and all secondary endpoints are reported here; health-related quality of life outcomes were assessed as exploratory endpoints and are planned to be published separately.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.4-2"></a>

##### In-trial qualitative interviews: design and sample of 91 participants

> “The trial included 60-minute, semi-structured, blinded, qualitative interviews (up to two) capturing participants’ descriptions of living with HAE, their attacks and associated symptoms, physical and emotional impacts of HAE, and fatigue/tiredness.”
> “A total of 141 interviews post attack (deucrictibant-treated, n=70; placebo-treated, n=71) were conducted with 91 of the 134 RAPIDe-3 participants across 19 countries.”
> “Of these, 50 participants across 16 countries completed the interviews for both attacks treated according to the crossover sequence; the remaining 41 participants completed an interview for a single attack during the study.”

Source: [Grumach et al. (2026)](https://ir.pharvaris.com/static-files/4dee9ac5-c7f0-489f-8d8a-197fc1d5da1a)

<a id="topic-3.1.1.8.4-3"></a>

##### In-trial qualitative interviews: attack-related impacts on health-related quality of life

> “Overall, participants reported experiencing eight negative HRQoL impacts with HAE attacks during the study, prior to the treatment with the study drug, in 113 interviews; the most frequently reported were fatigue (n=63/113 [55.8%]), emotional wellbeing (n=57/113 [50.4%]), and ADL (n=55/113 [48.7%])”
> “Despite using effective and well-tolerated HAE treatments in the past, 16/35 (45.7%) participants reported that deucrictibant-treated attacks had a lower negative impact on day-to-day life compared with prior attacks treated with other HAE treatments (Figure 5).”

Source: [Grumach et al. (2026)](https://ir.pharvaris.com/static-files/4dee9ac5-c7f0-489f-8d8a-197fc1d5da1a)

<a id="topic-3.1.1.8.4-4"></a>

##### In-trial qualitative interviews: on-demand treatments used before enrollment

> “All participants were asked about previous on-demand treatments used to treat HAE attacks before participating in RAPIDe-3: n=66/91 (72.5%) had used icatibant, n=41/91 (45.1%) human C1 inhibitor (C1INH), and n=7/91 (7.7%) recombinant C1INH.”
> “When participants (n=71) were asked to choose the most important aspect of their daily life they would have wanted to see improved with HAE treatment, 15/71 (21.1%) identified activities of daily living (ADL) and 14/71 (19.7%) said work/school (Figure 3).”

Source: [Grumach et al. (2026)](https://ir.pharvaris.com/static-files/4dee9ac5-c7f0-489f-8d8a-197fc1d5da1a)

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Treatment-emergent adverse events, safety analysis set

> “Summary of treatment-emergent adverse events in the safety analysis set”
> “N refers to the total number of participants with at least one dose of study drug.”
> “Adolescent participants only.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Event category | Non-attack deucrictibant (n=10): participants, n (%) | Non-attack: events, n | Treated attack deucrictibant (n=100): participants, n (%) | Deucrictibant: events, n | Treated attack placebo (n=101): participants, n (%) | Placebo: events, n |
| --- | --- | --- | --- | --- | --- | --- |
| Any treatment-emergent adverse event | “3 (30%)” | “4” | “24 (24%)” | “40” | “17 (17%)” | “22” |
| Any treatment-emergent adverse event related to study drug | “0” | “0” | “5 (5%)” | “6” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event | “0” | “0” | “1 (1%)” | “1” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event related to study drug | “0” | “0” | “0” | “0” | “0” | “0” |
| Any severe treatment-emergent adverse event | “0” | “0” | “1 (1%)” | “2” | “1 (1%)” | “3” |
| Any severe treatment-emergent adverse event related to study drug | “0” | “0” | “0” | “0” | “0” | “0” |
| Any treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “15 (15%)” | “17” | “2 (2%)” | “3” |
| Treatment-emergent adverse event within 3 days related to study drug | “0” | “0” | “5 (5%)” | “6” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “0” | “0” | “0” | “0” |
| Any severe treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “0” | “0” | “0” | “0” |
| Treatment-emergent adverse event leading to trial or study drug discontinuation | “0” | “0” | “0” | “0” | “0” | “0” |
| Treatment-emergent adverse event leading to death | “0” | “0” | “0” | “0” | “0” | “0” |
| Fatigue within 3 days post-treatment | “0” | “0” | “2 (2%)” | “2” | “0” | “0” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-2"></a>

##### Overall and 3-day adverse event rates, safety analysis set

> “Overall, 24 (24%) of 100 and 17 (17%) of 101 participants receiving deucrictibant and placebo, respectively, reported treatment-emergent adverse events (table 3).”
> “Treatment-emergent adverse events within 3 days post-treatment were reported by 15 (15%) and two (2%) participants receiving deucrictibant and placebo, respectively.”
> “In both groups, all events within 3 days were mild or moderate in severity.”
> “No treatment-emergent adverse events required emergency unmasking.”
> “A single event of fatigue occurred in two participants in the deucrictibant group within 3 days after treatment, one of which was deemed unrelated to treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-3"></a>

##### Treatment-related adverse events

> “Six events in five participants in the deucrictibant group were reported as related to treatment as deemed by the investigators, all of which were observed once and resolved within 24 h spontaneously or with standard management (table 3).”
> “One event each of dyspepsia, fatigue, lethargy, brain fog, headache, and somnolence in deucrictibant-treated patients, and one event of pruritus in placebo-treated patients.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-4"></a>

##### Serious and severe adverse events

> “One participant who treated the first and only attack with placebo had a serious event of spontaneous miscarriage, reported 45 days post-treatment, and three additional severe events: endometrial hyperplasia, endometrial cancer, and bladder transitional cell carcinoma.”
> “One participant reported a serious event of laryngeal hereditary angioedema attack that occurred 132 days following deucrictibant treatment and required admission to hospital.”
> “The same participant reported two severe events of back pain and sacral pain 68 days following treatment with deucrictibant.”
> “None of the serious or severe events were considered related to study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-5"></a>

##### Maximum severity grade of treatment-emergent adverse events, safety analysis set

| Participants with ≥1 TEAE by maximum grade | Placebo (N=101) | Deucrictibant (N=100) |
| --- | --- | --- |
| Any TEAEs | “17 (16.8)” | “24 (24.0)” |
| Maximum Grade 1 (Mild) | “10 (9.9)” | “13 (13.0)” |
| Maximum Grade 2 (Moderate) | “6 (5.9)” | “10 (10.0)” |
| Maximum Grade 3 (Severe) | “0” | “1 (1.0)” |
| Maximum Grade 4 (Life-threatening) | “1 (1.0)” | “0” |
| Maximum Grade 5 (Fatal) | “0” | “0” |

Source: [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404)

<a id="topic-3.1.1.8.5-6"></a>

##### Laboratory, vital sign, and electrocardiogram findings and discontinuations

> “During the entire study, no treatment-emergent adverse events led to treatment discontinuation, or were associated with changes in clinical laboratory, vital signs, and electrocardiogram parameters.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-7"></a>

##### Capsule ingestion during abdominal and laryngeal attacks

> “No issues with capsule ingestion, such as difficulty swallowing, were reported, including for laryngeal attacks, and no reports of vomiting following study drug administration were reported in participants with abdominal symptoms.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- The authors stated that “Limitations of this trial include the lack of attack stratification according to location and severity”, and that a larger proportion of severe attacks was therefore observed in the placebo group: severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Two non-severe laryngeal attacks were treated with deucrictibant and none with placebo.
- Severe laryngeal attacks were not included, because of the risks of random assignment to double-masked placebo, and adolescents were instructed to treat laryngeal attacks of any severity with conventional on-demand therapy.
- The sponsor ended the trial after the prespecified number of participants with paired attacks was reached and before all participants had treated two attacks. Of 134 enrolled participants, 113 treated at least one attack and 88 contributed paired attacks to the primary efficacy analysis. One participant randomized to the deucrictibant-placebo sequence was given placebo in error and treated no second attack.
- Each participant treated at most one attack with deucrictibant in the crossover, and safety comparisons were descriptive. Treatment-emergent adverse events within 3 days of study drug were considered temporally clinically relevant.
- Subgroups were small: ten (7%) enrolled participants were adolescents, five of them in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor.
- Eligibility required experience effectively using conventional on-demand therapy and excluded people older than 75 years, people with abnormal hepatic function or eGFR <60 ml/min/1.73 m2, users of strong CYP3A4 inhibitors or inducers, people with prior gene therapy, and pregnant or breastfeeding women.
- Use of rescue or selected prohibited medication was counted as treatment failure, and missing data at the end of follow-up were handled by right censoring without imputation.
- Health-related quality of life outcomes were exploratory endpoints planned for separate publication.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404); [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318); [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
